PRQR

ProQR Therapeutics N.V.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$1.63

Price (1 Year)

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %5.9 / %30

Non-compliant assets / Total market cap %23 / %30

Non-compliant income / Total income %30.6 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs.